1 option
Therapeutic strategies to overcome ALK resistance in cancer / edited by Luc Friboulet.
- Format:
- Book
- Series:
- Cancer sensitizing agents for chemotherapy ; 2468-3183 v. 13.
- Cancer sensitizing agents for chemotherapy ; volume 13
- Language:
- English
- Subjects (All):
- Lungs--Cancer--Treatment.
- Lungs.
- Anaplastic Lymphoma Kinase--antagonists & inhibitors.
- Lung Neoplasms--drug therapy.
- Antineoplastic Agents--pharmacology.
- Protein Kinase Inhibitors--therapeutic use.
- Medical Subjects:
- Anaplastic Lymphoma Kinase--antagonists & inhibitors.
- Lung Neoplasms--drug therapy.
- Antineoplastic Agents--pharmacology.
- Protein Kinase Inhibitors--therapeutic use.
- Genre:
- Electronic books.
- Physical Description:
- 1 online resource (xix, 195 pages) : illustrations (some color), portraits (some color).
- Place of Publication:
- London, United Kingdom : Academic Press, an imprint of Elsevier, [2021]
- System Details:
- text file
- Summary:
- "Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field"--Publisher's description.
- Contents:
- Structure and function of ALK
- ALK rearranged lung cancer: TKI treatment and outcome
- Systemic treatments other than TKI: reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC
- Management of ALK positive patients with tumors other than lung cancer (ALCL, neuroblastoma, inflammatory myofibroblastic tumor)
- Resistance mechanisms to ALK TKIs in lung cancer: from single to compound mutations, from tissue to liquid biopsy
- Resistance mechanisms to ALK TKI in tumors other than lung cancer
- Therapeutic strategies to overcome ALK resistance in lung cancer
- Novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL: use of ACD
- Drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma
- State of the art and future perspectives.
- Notes:
- Includes bibliographical references and index.
- Description based on online resource; title from electronic title page (ProQuest Ebook Central, viewed on June 21, 2021).
- Other Format:
- Print version : Therapeutic strategies to overcome ALK resistance in cancer.
- ISBN:
- 9780128217795
- 0128217790
- OCLC:
- 1233309760
- Access Restriction:
- Restricted for use by site license.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.